New hope for hard-to-treat cancers: experimental drug targets HER2-positive tumors
NCT ID NCT07309770
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called trastuzumab rezetecan in people with advanced solid tumors that have stopped responding to standard therapies. The drug is given every three weeks to 90 participants divided into three groups based on their cancer type. Researchers will measure how many tumors shrink or disappear and track side effects and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trastuzumab rezetecan (SHR-A1811), an antibody-drug conjugate
What this could lead to
If successful, this could offer a new treatment option for people with HER2-positive advanced solid tumors who have run out of standard therapies.
What could go wrong
This is an early-phase (Phase II) study with a small number of participants (90). It may not show enough benefit or could have side effects that limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY-DRUG CONJUGATES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••